10-Q: GoodRx Navigates Pharmacy Shifts, Posts Mixed Q3 Results

GoodRx reported a slight revenue increase but a significant net income drop in Q3 2025, as growth in pharma solutions was offset by declines in prescription transactions and active consumers amid retail pharmacy landscape changes.

Summary

• Total revenue for the three months ended September 30, 2025, increased slightly to $196.0 million, up from $195.3 million in the same period of 2024.
• Net income for Q3 2025 significantly decreased by 72.5% to $1.1 million, compared to $4.0 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 increased by 2% to $66.3 million, with an Adjusted EBITDA Margin of 33.8%.
• Prescription transactions revenue decreased by 9% year-over-year to $127.3 million in Q3 2025, primarily due to a decline in Monthly Active Consumers.
• Pharma manufacturer solutions revenue demonstrated strong growth, increasing by 54% year-over-year to $43.4 million in Q3 2025.
• Monthly Active Consumers declined to 5.4 million as of September 30, 2025, down from 6.5 million a year prior.
• Subscription plans decreased to 671 thousand as of September 30, 2025, from 701 thousand a year prior.
• Acquired substantially all of the assets and assembled workforce of VCRx for $30.0 million in cash on January 13, 2025.
• Accrued an estimated probable loss of $5.5 million in Q3 2025 related to the indemnification of certain parties in class action lawsuits.
• Cash and cash equivalents decreased to $273.5 million as of September 30, 2025, from $448.3 million at December 31, 2024.

Sentiment

Score: 4

Explanation: While pharma solutions show strong growth and Adjusted EBITDA is up, the significant decline in net income, core prescription transactions revenue, Monthly Active Consumers, and subscription plans, coupled with ongoing industry headwinds and legal expenses, indicates a challenging operating environment. The future outlook acknowledges continued adverse impacts in the near term.

Positives

• Pharma manufacturer solutions revenue increased by 54% to $43.4 million in Q3 2025 and 35% to $107.0 million for the nine months ended September 30, 2025, indicating strong growth in this segment.
• Adjusted EBITDA showed modest growth, increasing to $66.3 million in Q3 2025 (up 2%) and $205.5 million for the nine months (up 6.4%).
• Launched new condition-specific subscription programs for erectile dysfunction in Q2 2025 and expanded into hair loss in October 2025, diversifying service offerings.
• Announced a collaboration with a pharmaceutical manufacturer to offer eligible patients GLP-1 medications at a significantly lower cash price through the platform.
• Successfully acquired VCRx for $30.0 million in January 2025 and ScriptDrop, Inc. for $13.5 million in October 2025, expanding business capabilities and prescription delivery solutions.
• Maintained compliance with debt covenants, with $80.2 million available under the revolving credit facility as of September 30, 2025.

Negatives

• Net income for Q3 2025 significantly decreased by 72.5% to $1.1 million from $4.0 million in Q3 2024.
• Prescription transactions revenue declined by 9% to $127.3 million in Q3 2025, primarily due to a decrease in Monthly Active Consumers.
• Monthly Active Consumers decreased by 16.9% to 5.4 million as of September 30, 2025, from 6.5 million a year prior.
• Subscription revenue decreased by 3% to $20.7 million in Q3 2025, with subscription plans declining by 4.3% to 671 thousand.
• Cash and cash equivalents decreased by $174.8 million from December 31, 2024, to September 30, 2025.
• Accrued an additional $5.5 million probable loss in Q3 2025 for indemnification related to class action lawsuits.
• Operating income decreased to $14.6 million in Q3 2025 from $20.4 million in Q3 2024.
• Interest income decreased by 52% year-over-year in Q3 2025 due to lower average cash equivalent balances and lower interest rates.

Risks

• Ongoing changes in the U.S. retail pharmacy landscape, including store closures (e.g., Rite Aid, Walgreens) and the bankruptcy of a retail partner, have adversely impacted prescription transactions revenue and Monthly Active Consumers.
• PBMs removing Rite Aid from their networks caused immediate cessation in associated claims volume and rapid store closures, making recapture of claims difficult.
• Heightened renegotiations between pharmacies and PBMs, including changes in retailer reimbursement models, are expected to continue.
• A material volume reduction occurred in one of the integrated savings programs, negatively impacting prescription transactions revenue.
• The new government-sponsored direct-to-consumer platform TrumpRx.gov and potential 100% tariffs on foreign-produced pharmaceutical products introduce significant uncertainty and potential adverse impacts on business, offerings, or results of operations.
• Congress passed the One Big Beautiful Bill Act (OBBBA) in July 2025, cutting federal funding for Medicaid and tightening eligibility, which may increase the number of uninsured individuals and affect prescription access.
• Heightened governmental scrutiny of PBMs, including an FTC administrative complaint alleging anti-competitive practices, could lead to further regulation impacting the industry.
• State-level legislation and regulations designed to control medication pricing, including prescription drug affordability boards, could impose price limits and affect business.
• The company is subject to various legal proceedings and claims, including consumer privacy class actions and state litigations, which may require significant funds and diversion of resources, and actual losses may differ from estimates.
• The ability to realize expected benefits from restructuring and cost reduction efforts is uncertain.
• Dependence on information technology systems and third-party vendors, with risks related to failures or disruptions.
• Risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology, and cybersecurity.
• The current economic uncertainty, including rising inflation and interest rates, could reduce the ability to access capital on favorable terms.

Future Outlook

GoodRx expects to continue expanding into additional condition-specific subscription programs before the end of 2025. Pharma manufacturer solutions are anticipated to grow as a percentage of total revenue in the near to medium term. However, the company projects that adverse impacts on prescription transactions revenue, financial results, and Monthly Active Consumers from external factors (such as retail pharmacy landscape changes and integrated savings program volume reduction) will continue in the near term, with an estimated impact to prescription transactions revenue of $35.0 million to $40.0 million in 2025. GoodRx believes its net cash provided by operating activities and cash on hand will be adequate to meet operating, investing, and financing needs for at least the next twelve months, but acknowledges that future capital requirements may necessitate additional indebtedness or equity financings, which may not be available on favorable terms.

Management Comments

• "Our mission is to help Americans save time and money when filling their medications."
• "We plan to continue to expand into additional conditions before the end of 2025."
• "As insurance providers and government programs continue to shift the cost burden more to consumers, including through changes to Affordable Care Act marketplace subsidies, consumers are now more than ever searching for sustainable and affordable healthcare solutions which we believe strengthens our value proposition."
• "Details regarding this government sponsored platform [TrumpRx.gov], as well as any potential impact on our business, offerings or results of operations, are unclear at this time but may be significant."
• "We are actively engaged with the administration, helping to inform policy efforts that expand access and affordability for all Americans."
• "With the introduction of these federal initiatives, including the renewed focus on Most-Favored-Nation pricing, the market is shifting decisively toward greater transparency and direct-to-consumer access. For us, this evolution is both an opportunity and a clear validation of our mission."
• "Despite these near term challenges, we continue to believe that we are well positioned to grow our business over the long term."
• "As our business continues to evolve, we are reassessing the Monthly Active Consumers metric as a primary indicator of performance to ensure it aligns with how we measure growth and profitability."

Industry Context

The U.S. retail pharmacy landscape is undergoing rapid changes, including store closures (e.g., Rite Aid, Walgreens) and the bankruptcy of Rite Aid, leading to PBMs removing Rite Aid from their networks and impacting claims volume. The healthcare industry is experiencing increased governmental scrutiny, with new federal initiatives like TrumpRx.gov and the One Big Beautiful Bill Act (OBBBA) impacting Medicaid funding and potentially imposing tariffs on pharmaceutical products. There's a shifting market towards greater transparency and direct-to-consumer access in prescription pricing, which GoodRx views as both an opportunity and validation of its mission. Copays on prescription medication continue to trend upward, increasing the burden on consumers and driving demand for affordable healthcare solutions. Ongoing renegotiations between pharmacies and PBMs, including changes in retailer reimbursement models, are a result of pharmacies' increased focus on rationalizing spending.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks or industry standards.

Legal Proceedings

• **Consumer Privacy Class Action (NDCA Class Action Matter)**: A proposed settlement of $25.0 million was denied preliminary approval by the court on June 12, 2025, with leave to refile. An estimated probable loss of $25.0 million remains accrued as of September 30, 2025.
• **Indemnification for Class Action Lawsuits**: An estimated probable loss of $5.5 million was accrued in Q3 2025 relating to the indemnification of certain parties named in the class action lawsuits.
• **Consumer State Litigations (Arkansas)**: The Bert and Annette Mullens Foundation filed a lawsuit alleging violations of an Arkansas statute related to health-related discount cards. A motion to dismiss was denied on December 2, 2024. The Arkansas Attorney General intervened on May 9, 2025. Separately, the State of Arkansas entered a Consent Judgment on September 25, 2025, releasing GoodRx from certain claims for an immaterial monetary relief.
• **Consumer State Litigations (Minnesota)**: The Minnesota Teamsters Service Bureau filed a lawsuit alleging violations of a Minnesota statute related to health-related discount cards. A motion to dismiss was denied on December 17, 2024. The court granted a motion to dismiss some of GoodRx's counterclaims on June 10, 2025. Summary judgment motions were filed on October 10, 2025.
• **Arbitration Award (GoodRx as Plaintiff)**: An arbitration award was rendered on February 15, 2024, against Famulus Health, LLC for breach of agreement, which included damages and a permanent injunction. The U.S. District Court for the District of South Carolina confirmed the award (as modified) on September 11, 2024, and a writ of execution was issued on October 16, 2024. The collection of this award is uncertain.

Related Party Transactions

• In March 2025, repurchased 20.0 million shares of Class A common stock from related parties (Francisco Partners, Idea Men, LLC, and Spectrum) for an aggregate consideration of $84.9 million.
• In March 2024, repurchased 20.9 million shares of Class A common stock from related parties (Francisco Partners and Spectrum) for an aggregate consideration of $151.4 million.

Stakeholder Impact

• **Shareholders**: Impacted by declining core business metrics, significant Q3 net income drop, and ongoing legal expenses, potentially affecting share price. The stock repurchase program provides some capital return.
• **Consumers**: Benefit from new condition-specific subscription programs and collaborations offering lower cash prices for medications (e.g., GLP-1s). However, the decline in Monthly Active Consumers and subscription plans suggests some consumers are not finding value or are impacted by pharmacy landscape changes.
• **Employees**: Changes in employee composition were noted as a driver for decreased stock-based compensation expense in sales and marketing. Restructuring related expenses include employee severance.
• **Pharmacies/PBMs**: The changing retail pharmacy landscape, including store closures and PBM network removals, directly impacts GoodRx's prescription transactions offering. Heightened renegotiations between pharmacies and PBMs are ongoing.
• **Pharma Manufacturers**: Benefit from GoodRx's expanding pharma manufacturer solutions, but face potential impacts from government initiatives like TrumpRx.gov and tariffs.

Next Steps

• Continue to expand into additional condition-specific subscription programs before the end of 2025.
• Actively engage with the administration to inform policy efforts that expand access and affordability for Americans.
• Evaluate the impact of new accounting standards (ASU 2025-06, ASU 2025-05, ASU 2024-03, ASU 2023-09) on consolidated financial statements.
• Vigorously defend against claims asserted in The Bert and Annette Mullens Foundation matter and the Minnesota Teamsters Service Bureau matters.
• Seek to collect the arbitration award against Famulus Health, LLC.

Key Dates

Recommendation

GoodRx faces significant headwinds from a changing retail pharmacy landscape, declining core user metrics (Monthly Active Consumers and subscription plans), and increased regulatory scrutiny. While the Pharma Manufacturer Solutions segment shows strong growth and the company is strategically expanding into new condition-specific offerings and acquisitions, these positives are currently offset by a substantial drop in Q3 net income and ongoing legal liabilities. The near-term outlook for prescription transactions revenue is also negative. An investor should hold to monitor the effectiveness of new strategic initiatives and the company's ability to navigate the challenging industry and regulatory environment, particularly the impact of government platforms like TrumpRx.gov and PBM renegotiations. The stock repurchase program provides some support, but the core business challenges warrant caution.

Keywords

GoodRx, GDRX, prescription savings, pharmacy benefit manager, PBM, pharma manufacturer solutions, telehealth, prescription delivery, stock repurchase, legal proceedings, consumer privacy, healthcare industry, TrumpRx.gov, Medicaid, GLP-1, VCRx, ScriptDrop